GDC-0032 (taselisib) is a potent, selective inhibitor of Class I phosphoinositide 3-kinase (PI3K) alpha, delta, and gamma isoforms, with approximately 30-fold less inhibition of the p110 beta isoform.
PI3K is a lipid kinase involved in tumor cell proliferation, survival, and migration upon activation by growth factor receptors and integrins. PI3K catalyzes the phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3), a second messenger involved in the phosphorylation of Akt and associated proteins in the Akt/mammalian target of rapamycin (mTOR) pathway. Activating and transforming mutations of the gene encoding the p110 alpha subunit of PI3K (PIK3CA) are commonly found in solid and hematological tumors
This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors or lymphomas.